Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
32
AVIR Quote, Financials, Valuation and Earnings
Last price:
$3.18
Seasonality move
:
-23.12%
Day range:
$3.08 - $3.19
52-week range:
$2.46 - $4.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.84x
P/B ratio:
0.78x
Volume:
268.3K
Avg. volume:
417.4K
1-year change:
8.19%
Market cap:
$247.7M
Revenue:
--
EPS (TTM):
-$1.78
Analysts' Opinion
-
Consensus RatingAtea Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.00, Atea Pharmaceuticals, Inc. has an estimated upside of 89.27% from its current price of $3.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $3.17.
Fair Value
-
According to the consensus of 3 analysts, Atea Pharmaceuticals, Inc. has 89.27% upside to fair value with a price target of $6.00 per share.
AVIR vs. S&P 500
-
Over the past 5 trading days, Atea Pharmaceuticals, Inc. has overperformed the S&P 500 by 1.94% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Atea Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Atea Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Atea Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Atea Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Atea Pharmaceuticals, Inc. reported earnings per share of -$0.53.
Enterprise value:
-80.6M
EV / Invested capital:
-0.25x
Price / LTM sales:
0.84x
EV / EBIT:
--
EV / Revenue:
-0.29x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$416K
Return On Assets:
-34.51%
Net Income Margin (TTM):
--
Return On Equity:
-36.97%
Return On Invested Capital:
-36.83%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$416K | -$416K | -$416K | -$104K | -$104K | |
| Operating Income | -$157.5M | -$200.5M | -$165M | -$37.2M | -$45.6M | |
| EBITDA | -$157.1M | -$200.1M | -$164.6M | -$37.1M | -$45.5M | |
| Diluted EPS | -$1.57 | -$2.07 | -$1.78 | -$0.37 | -$0.53 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $842.9M | $681.9M | $603.3M | $486.9M | $336.1M | |
| Total Assets | $843.5M | $686.6M | $608.1M | $491M | $343M | |
| Current Liabilities | $262.1M | $15.6M | $18.9M | $25.2M | $20.2M | |
| Total Liabilities | $262.1M | $23.4M | $26.3M | $32.4M | $27.2M | |
| Total Equity | $581.5M | $663.2M | $581.7M | $458.5M | $315.8M | |
| Total Debt | $279K | $2.6M | $1.8M | $1M | $213K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$85.1M | -$126.9M | -$134.2M | -$23M | -$40.4M | |
| Cash From Investing | $46M | $87.2M | $138.8M | -$122M | $41.3M | |
| Cash From Financing | $257K | $267K | -$25.7M | $117K | -$11.3M | |
| Free Cash Flow | -$85.1M | -$126.9M | -$134.2M | -$23M | -$40.4M | |
AVIR
Sector
Market Cap
$247.7M
$28.5M
Price % of 52-Week High
78.86%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
11.24%
-1.33%
1-Year Price Total Return
8.19%
-20.32%
Beta (5-Year)
0.159
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.08
200-day SMA
Sell
Level
$3.17
Bollinger Bands (100)
Sell
Level
3 - 3.5
Chaikin Money Flow
Sell
Level
-40.3M
20-day SMA
Buy
Level
$3.11
Relative Strength Index (RSI14)
Buy
Level
53.47
ADX Line
Buy
Level
9.52
Williams %R
Sell
Level
-7.4074
50-day SMA
Buy
Level
$3.12
MACD (12, 26)
Sell
Level
-0.02
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Sell
Level
-164.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.2583)
Buy
CA Score
(Annual)
Level (-0.0962)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (9.4327)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, AVIR has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The AVIR average analyst price target in the past 3 months is $6.00.
-
Where Will Atea Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Atea Pharmaceuticals, Inc. share price will rise to $6.00 per share over the next 12 months.
-
What Do Analysts Say About Atea Pharmaceuticals, Inc.?
Analysts are divided on their view about Atea Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Atea Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Atea Pharmaceuticals, Inc.'s Price Target?
The price target for Atea Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $6.00 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is AVIR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Atea Pharmaceuticals, Inc. is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AVIR?
You can purchase shares of Atea Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Atea Pharmaceuticals, Inc. shares.
-
What Is The Atea Pharmaceuticals, Inc. Share Price Today?
Atea Pharmaceuticals, Inc. was last trading at $3.18 per share. This represents the most recent stock quote for Atea Pharmaceuticals, Inc.. Yesterday, Atea Pharmaceuticals, Inc. closed at $3.17 per share.
-
How To Buy Atea Pharmaceuticals, Inc. Stock Online?
In order to purchase Atea Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get AVIR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AVIR
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
0.78x
1.83x
Price / LTM sales
0.84x
1.60x
Growth Metrics
AVIR
Sector
Revenue growth
--
4.85%
Earnings growth
-44.15%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.42
-$0.20
Profitability
AVIR
Sector
Profitability FY 2024
-$416K
$3.6M
Return on invested capital
-36.83%
-30.98%
Return on assets
-34.51%
-27.62%
Return on equity
-36.97%
-36.69%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
11
Balance Sheet
AVIR
Sector
Total cash
$329.3M
$27.2M
Short term investments
$390M
$25.7M
Total assets
$464.7M
$79.7M
Long term debt
$213K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
